Korsana (KRSA) Stock Analysis: Ratings, Forecast & Price Target

Stock Overview

4.52 / 10Overall Score

NeutralInvestment Rating

RiskExcellent

Drawing on fundamental quality of 4.60/10, technical read of 5.00/10, and market sentiment of 3.96/10, KRSA's overall diagnostic stands at 4.52/10 — a Neutral rating.
The five-dimensional fundamental profile of KRSA — Value 1.30, Future 5.50, Past 6.80, Health 5.50, Dividend 4.00 — aggregates to 4.60/10, earning a Neutral rating.
Weighing recent momentum, trend, and candlestick pattern signals, KRSA's technical footprint settles at 5.00/10 — rated Neutral.
The combined read of institutional fund flow activity and sell-side analyst consensus places KRSA's market sentiment at 3.96/10 — a Neutral rating.

Shareholder Returns

KRSAIndustryMarket

7 Day+19.2%-0.4%-1.1%

30 Day0.0%-1.7%-2.4%

90 Day0.0%+159.0%+1.0%

1 Year0.0%+214.5%+14.3%

3 Year0.0%+239.2%+77.0%

5 Year------

Include Dividend Returns

Is KRSA overvalued?

Return vs Industry: KRSA underperformed the Chemical Pharmaceuticals industry which returned 214.5% over the past year.

Return vs Market: KRSA underperformed the US Market which returned 14.2% over the past year.

Korsana Corporation Fundamentals Summary

-229.0xP/E Ratio

6.7xP/S Ratio

301.9xP/B Ratio

Market cap1.54B

Earnings-670.70M

Revenue23.06B

Is KRSA overvalued?

Valuation Snapshot: KRSA's current P/E ratio is -229.0x with TTM earnings of -670.70M. The stock trades at 6.7x revenue, reflecting modest market expectations for future growth.

Market Position: With a market capitalization of 1.54B and TTM revenue of 23.06B, KRSA is a smaller player in the Chemical Pharmaceuticals industry.